Goldman Sachs has downgraded its rating for Novo Nordisk from “buy” to “neutral” following disappointing phase 3 clinical trial results for the company’s next-generation obesity medicine,...
Investment firm Virtus SGA has decided to liquidate its position in Novo Nordisk, citing significant concerns regarding the pharmaceutical company’s long-term growth prospects. This decision follows...
